Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Plenamine is a sterile, nonpyrogenic 15% solution of essential and non-essential amino acids used for parenteral nutrition to provide a source of nitrogen for protein synthesis. In a clinical study led by Boston Medical Center, it was evaluated as an early supplemental intravenous protein source alongside enteral feeding for patients with traumatic injuries. The intervention aims to improve nitrogen balance and support the metabolic demands of the inflammatory response post-injury, potentially altering the metabolomic profile of critically ill patients in the surgical intensive care unit (SICU). By providing a concentrated source of protein (approximately 1.5-2.0 g/kg/day), it aims to mitigate the catabolic state typically seen in critically ill trauma patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Plenamine.